Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3

Conditions

Breast Neoplasms 544Neoplasms 384Carcinoma, Non-Small-Cell Lung 325Colorectal Neoplasms 296Lung Neoplasms 237Prostatic Neoplasms 220Carcinoma, Hepatocellular 213Stomach Neoplasms 155Pancreatic Neoplasms 155Leukemia, Myeloid, Acute 141Uterine Cervical Neoplasms 132Multiple Myeloma 130Recurrence 120Rectal Neoplasms 114Ovarian Neoplasms 109Neoplasm Metastasis 105Squamous Cell Carcinoma of Head and Neck 98Head and Neck Neoplasms 91Triple Negative Breast Neoplasms 87Esophageal Neoplasms 84Glioblastoma 82Endometrial Neoplasms 80Small Cell Lung Carcinoma 79Brain Neoplasms 79Colonic Neoplasms 78Melanoma 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 65Hematologic Neoplasms 65Glioma 63Disease 60

Interventions

famitinib 2camrelizumab 2toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Cervical Cancer Metastatic × Clear all
NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Shanghai Jiatan Pharmatech Co., Ltd

Phase 3 Not yet recruiting
440 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT07266350 2025-12-05

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Chongqing University Cancer Hospital

Not yet recruiting
1,300 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
120 enrolled
Gynecologic

Cervical Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡